273 related articles for article (PubMed ID: 24940767)
1. Aberrant regulation of alternative pre-mRNA splicing in hepatocellular carcinoma.
Liu L; Xie S; Zhang C; Zhu F
Crit Rev Eukaryot Gene Expr; 2014; 24(2):133-49. PubMed ID: 24940767
[TBL] [Abstract][Full Text] [Related]
2. Relationship between changes in the exon-recognition machinery and SLC22A1 alternative splicing in hepatocellular carcinoma.
Soto M; Reviejo M; Al-Abdulla R; Romero MR; Macias RIR; Boix L; Bruix J; Serrano MA; Marin JJG
Biochim Biophys Acta Mol Basis Dis; 2020 May; 1866(5):165687. PubMed ID: 31953214
[TBL] [Abstract][Full Text] [Related]
3. Alternative mRNA splicing of liver intestine-cadherin in hepatocellular carcinoma.
Wang XQ; Luk JM; Leung PP; Wong BW; Stanbridge EJ; Fan ST
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):483-9. PubMed ID: 15701831
[TBL] [Abstract][Full Text] [Related]
4. Prognostic index of aberrant mRNA splicing profiling acts as a predictive indicator for hepatocellular carcinoma based on TCGA SpliceSeq data.
Wu HY; Peng ZG; He RQ; Luo B; Ma J; Hu XH; Dang YW; Chen G; Pan SL
Int J Oncol; 2019 Aug; 55(2):425-438. PubMed ID: 31268164
[TBL] [Abstract][Full Text] [Related]
5. Identification of important long non-coding RNAs and highly recurrent aberrant alternative splicing events in hepatocellular carcinoma through integrative analysis of multiple RNA-Seq datasets.
Zhang L; Liu X; Zhang X; Chen R
Mol Genet Genomics; 2016 Jun; 291(3):1035-51. PubMed ID: 26711644
[TBL] [Abstract][Full Text] [Related]
6. Aberrant splicing of Hugl-1 is associated with hepatocellular carcinoma progression.
Lu X; Feng X; Man X; Yang G; Tang L; Du D; Zhang F; Yuan H; Huang Q; Zhang Z; Liu Y; Strand D; Chen Z
Clin Cancer Res; 2009 May; 15(10):3287-96. PubMed ID: 19447873
[TBL] [Abstract][Full Text] [Related]
7. DIS3L2 Promotes Progression of Hepatocellular Carcinoma via hnRNP U-Mediated Alternative Splicing.
Xing S; Li Z; Ma W; He X; Shen S; Wei H; Li ST; Shu Y; Sun L; Zhong X; Huangfu Y; Su L; Feng J; Zhang X; Gao P; Jia WD; Zhang H
Cancer Res; 2019 Oct; 79(19):4923-4936. PubMed ID: 31331910
[TBL] [Abstract][Full Text] [Related]
8. [Pre-mRNA alternative splicing in cancer: functional impact, molecular mechanisms and therapeutic perspectives].
Revil T; Shkreta L; Chabot B
Bull Cancer; 2006 Sep; 93(9):909-19. PubMed ID: 16980234
[TBL] [Abstract][Full Text] [Related]
9. Global profiling of alternative RNA splicing events provides insights into molecular differences between various types of hepatocellular carcinoma.
Tremblay MP; Armero VE; Allaire A; Boudreault S; Martenon-Brodeur C; Durand M; Lapointe E; Thibault P; Tremblay-Létourneau M; Perreault JP; Scott MS; Bisaillon M
BMC Genomics; 2016 Aug; 17(1):683. PubMed ID: 27565572
[TBL] [Abstract][Full Text] [Related]
10. Alternative Splicing in Hepatocellular Carcinoma.
Lee SE; Alcedo KP; Kim HJ; Snider NT
Cell Mol Gastroenterol Hepatol; 2020; 10(4):699-712. PubMed ID: 32389640
[TBL] [Abstract][Full Text] [Related]
11. Long-Read RNA Sequencing Identifies Alternative Splice Variants in Hepatocellular Carcinoma and Tumor-Specific Isoforms.
Chen H; Gao F; He M; Ding XF; Wong AM; Sze SC; Yu AC; Sun T; Chan AW; Wang X; Wong N
Hepatology; 2019 Sep; 70(3):1011-1025. PubMed ID: 30637779
[TBL] [Abstract][Full Text] [Related]
12. Impairment of pre-mRNA splicing in liver disease: mechanisms and consequences.
Berasain C; Goñi S; Castillo J; Latasa MU; Prieto J; Avila MA
World J Gastroenterol; 2010 Jul; 16(25):3091-102. PubMed ID: 20593494
[TBL] [Abstract][Full Text] [Related]
13. SRSF3 Depletion Leads to an Increase in SF3B4 Expression in SNU-368 HCC Cells.
Lee J; Seo G; Hur W; Yoon SK; Nam SW; Lee JH
Anticancer Res; 2020 Apr; 40(4):2033-2042. PubMed ID: 32234894
[TBL] [Abstract][Full Text] [Related]
14. Alternative pre-mRNA splicing in digestive tract malignancy.
Miura K; Fujibuchi W; Sasaki I
Cancer Sci; 2011 Feb; 102(2):309-16. PubMed ID: 21134075
[TBL] [Abstract][Full Text] [Related]
15. SRSF2 Regulates Alternative Splicing to Drive Hepatocellular Carcinoma Development.
Luo C; Cheng Y; Liu Y; Chen L; Liu L; Wei N; Xie Z; Wu W; Feng Y
Cancer Res; 2017 Mar; 77(5):1168-1178. PubMed ID: 28082404
[TBL] [Abstract][Full Text] [Related]
16. In vivo expression patterns of survivin and its splicing variants in chronic liver disease and hepatocellular carcinoma.
Takashima H; Nakajima T; Moriguchi M; Sekoguchi S; Nishikawa T; Watanabe T; Katagishi T; Kimura H; Minami M; Itoh Y; Kagawa K; Okanoue T
Liver Int; 2005 Feb; 25(1):77-84. PubMed ID: 15698402
[TBL] [Abstract][Full Text] [Related]
17. Role of IQGAP3 in metastasis and epithelial-mesenchymal transition in human hepatocellular carcinoma.
Shi Y; Qin N; Zhou Q; Chen Y; Huang S; Chen B; Shen G; Jia H
J Transl Med; 2017 Aug; 15(1):176. PubMed ID: 28810875
[TBL] [Abstract][Full Text] [Related]
18. Decoding the role of aberrant RNA alternative splicing in hepatocellular carcinoma: a comprehensive review.
Sheng M; Zhang Y; Wang Y; Liu W; Wang X; Ke T; Liu P; Wang S; Shao W
J Cancer Res Clin Oncol; 2023 Dec; 149(19):17691-17708. PubMed ID: 37898981
[TBL] [Abstract][Full Text] [Related]
19. Mitogenic insulin receptor-A is overexpressed in human hepatocellular carcinoma due to EGFR-mediated dysregulation of RNA splicing factors.
Chettouh H; Fartoux L; Aoudjehane L; Wendum D; Clapéron A; Chrétien Y; Rey C; Scatton O; Soubrane O; Conti F; Praz F; Housset C; Rosmorduc O; Desbois-Mouthon C
Cancer Res; 2013 Jul; 73(13):3974-86. PubMed ID: 23633480
[TBL] [Abstract][Full Text] [Related]
20. Variant 2 of KIAA0101, antagonizing its oncogenic variant 1, might be a potential therapeutic strategy in hepatocellular carcinoma.
Liu L; Liu Y; Chen X; Wang M; Zhou Y; Zhou P; Li W; Zhu F
Oncotarget; 2017 Jul; 8(27):43990-44003. PubMed ID: 28410205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
